This article discusses the effectiveness and safety of anti-IL-23 and anti-IL-17 biological therapies for psoriasis in elderly patients. The study collected data from two Italian hospitals and evaluated the outcomes of over-65 patients receiving these treatments. The results showed that these therapies were effective in improving psoriasis symptoms in elderly patients, with a high percentage of patients achieving significant improvement. The study also found that the treatments were generally well-tolerated, with no severe adverse events reported. However, further research is needed to evaluate the effectiveness and safety of newer biologics in older patients. [Extracted from the article]